Brief: Transgene Says Financial Visibility Extended Until End 2023

Transgene SA

22/09/2021 17:04

Sept 22 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE’S TWO INNOVATIVE PLATFORMS PROGRESSING WELL -
FINANCIAL VISIBILITY EXTENDED UNTIL END 2023
    * TG4050 (MYVAC® PLATFORM) - FIRST DATA EXPECTED FROM TWO
PHASE I
TRIALS IN SECOND HALF OF NOVEMBER 2021
    * TG4001 - FIRST PATIENTS ENROLLED IN A RANDOMIZED PHASE II
CLINICAL TRIAL - INTERIM RESULTS EXPECTED AROUND END OF 2022
    * BT-001 (LEAD INVIR.IO™ CANDIDATE) - FIRST PATIENTS
ENROLLED IN
PHASE I/IIA TRIAL AND US IND CLEARANCE RECEIVED - FIRST DATA
EXPECTED IN H1 2022
    * EUR 48.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF JUNE
30,
2021

Source text for Eikon:  ID:nBw6bz392a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))